Other Events ·
Immutep reports positive Phase I data for LAG-3 agonist IMP761 in autoimmune disease
IMMPIMMUTEP Ltd
Immutep announced statistically significant, exposure-dependent inhibition of T-cell-driven immune responses from a Phase I study of its first-in-class LAG-3 agonist antibody, IMP761. The trial in healthy volunteers demonstrated that the drug was well tolerated across seven dose levels with no serious adverse events and supports a four-week dosing interval. Results are expected to inform future Phase II programs for autoimmune diseases. Immutep is a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune disease.